Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q1 2024 · 10-Q
Revenue$35.72K$35.72K— vs Q1 2023 Net Income-$1.28M-$1.28MN/M vs Q1 2023 EPS Diluted-$0.47-$0.47no prior Q1 2023 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Operating Cash Flow-$1,699,118N/M Margins · derivedGross margin35.0%
Operating margin-3571.8%
Net margin-3579.2%
ended Mar 31, 2024 · filed May 13, 2024 · 43 d after period end